Sign in
WithdrawnNo phase

Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct

Key facts

Who runs it
Corewell Health East
Trial code
Status
Withdrawn
Started
Jun 2023
Ended
Jun 2024
Type of study
Interventional
Treatments tested
  • CTA/FFRct
  • SOC cardiovascular evaluation
Record updated
2 March 2023
Why it stopped
Essential staff for study execution left the institution and no suitable replacement could be found.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients with end-stage liver disease
  • Patients undergoing cardiovascular risk assessment prior to liver transplantation -

Who cannot take part

  • Heart rate > 90 bpm despite beta blocker therapy
  • Estimated Glomerular Filtration Rate (eGFR) < 30 cc/min/1.73 m\^2 (unless patient is on dialysis or renal transplant is planned)
  • Body Mass Index (BMI) > 40 plus chest obesity (i.e. truncal obesity and normal chest morphology is not an exclusion)
  • Pregnant Women

About the trial

What the trial wants to find out

Coronary Artery Disease (CAD) is the narrowing or blockage of the artery of the heart and is prevalent in end-stage liver disease. Consultation with cardiologist and stress tests are recommended to patients under consideration for liver transplant. The purpose of this study is to evaluate if Computed Tomography Angiogram (CTA) and CTA-derived Fractional Flow Reserve (FFRct) procedure influences decisions about further cardiac testing compared with Standard of Care (SOC) such as consultation by a cardiologist, Echocardiogram (ultrasound of the heart), Electrocardiogram (ECG) and stress tests.

The group in the trial

  • Evaluation of Standard of care followed by CTA/FFRctTreatment being tested

    Patient received clinical recommendation based on the Standard of Care i.e 2 D echocardiogram, plus ECG, plus, pharmacological stress test followed by re-evaluation of clinical recommendation with addition of CTA/FFRct

    Treatment: CTA/FFRct and SOC cardiovascular evaluation

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct in Patients With End-Stage Liver Disease Under Consideration for Liver Transplant.
Record updated
2 March 2023